Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Cardiovascular Diseases Eye Diseases Glaucoma Glaucoma, Open-Angle Hypertension Ocular Hypertension Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alcon Clinical Trial Sites

Multiple Locations Throughout the US Sponsored by Alcon of, Texas, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;
logMAR visual acuity not worse than 0.6.

Exclusion criteria

Clinically relevant ophthalmic or systemic conditions may be excluded.

Treatment and study plan

Glaucoma therapy

Drug

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 1999
Primary completion: 2003
Study completion: 2003
First posted: Oct 6, 2003
Registry last updated: Aug 5, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed